THE "NEW" PROSTATE CANCER INFOLINK

At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group.

For the many patients and advocates who may have felt that the “old Dendreon” had failed to invest in and develop the full potential of sipuleucel-T (Provenge), this looks like a new beginning, and a corporate media release from Dendreon certainly seems to support that view. So, …

Can the “new Dendreon” really deliver on the potential of Provenge? We’ll have to wait and see, but if they are going to be able to do this it is going to involve several major new trials of the product (and probably much earlier in the progression of prostate cancer).

Seven years after Provenge was originally approved by the US Food and Drug Administration, it is still the only form of immunotherapy ever approved in the treatment of prostate cancer.

Filed under: Drugs in development, Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T |